Create a management protocol for sepsis in the ICU
Reading Document
Medical Text Search
sepsis ICU management protocol diagnosis criteria Surviving Sepsis Campaign
Medical Text Search
sepsis fluid resuscitation vasopressors antibiotics source control
GradeResponse
GradeResponse
Medical Text Search
sepsis empiric antibiotic therapy broad spectrum de-escalation blood cultures
I have solid evidence from both sources. I'll now synthesize a comprehensive ICU sepsis management protocol.
ICU Sepsis Management Protocol
Based on the Surviving Sepsis Campaign (SSC) Guidelines, Harrison's Principles of Internal Medicine (21st Ed.), and Bailey & Love's Short Practice of Surgery (28th Ed.)
1. Definitions
| Term | Definition |
|---|---|
| Sepsis | Life-threatening organ dysfunction caused by a dysregulated host response to infection (SOFA score ≥2 from baseline) |
| Septic Shock | Sepsis + vasopressor requirement to maintain MAP ≥65 mmHg + serum lactate >2 mmol/L despite adequate fluid resuscitation |
| qSOFA (screening) | ≥2 of: RR ≥22/min, altered mentation (GCS <15), SBP ≤100 mmHg |
2. Immediate Recognition & Triage
- Screen all ICU admissions using qSOFA at the bedside; confirm with full SOFA score
- Obtain serum lactate immediately — lactate >2 mmol/L is a red flag; >4 mmol/L indicates tissue hypoperfusion regardless of blood pressure
- Declare a Sepsis Alert when criteria are met — time zero starts here
3. The 1-Hour Bundle (SSC 2018)
These actions should be initiated simultaneously, not sequentially:
- Measure lactate — repeat if initial >2 mmol/L to confirm clearance
- Blood cultures × 2 (aerobic + anaerobic) from two separate sites — before antibiotics if possible without delaying therapy >45 min
- Administer broad-spectrum antibiotics (see Section 5)
- Begin IV crystalloid resuscitation — 30 mL/kg for hypotension or lactate ≥4 mmol/L
- Start vasopressors if hemodynamically unstable during or after fluids — target MAP ≥65 mmHg
4. Fluid Resuscitation
| Parameter | Recommendation |
|---|---|
| Initial bolus | 30 mL/kg IV crystalloid within first 3 hours |
| Preferred fluid | Balanced crystalloids (e.g., Lactated Ringer's) or normal saline |
| Avoid | Hydroxyethyl starches (HES), gelatins |
| Reassessment tool | Focused cardiac ultrasound (bedside echo) if diagnosis unclear |
| Resuscitation target | Normalize lactate; target MAP ≥65 mmHg; avoid fluid overload |
Reassess volume status dynamically using passive leg raise, pulse pressure variation, or stroke volume variation to guide ongoing fluid therapy beyond the initial bolus.
5. Antimicrobial Therapy
Timing
- Administer within 1 hour of sepsis recognition
- Each hour of delay worsens mortality
Empiric Regimen Selection
| Clinical Context | Empiric Regimen |
|---|---|
| Community-acquired, no risk factors | Piperacillin-tazobactam OR a 3rd/4th generation cephalosporin ± metronidazole |
| Hospital-acquired / VAP / immunocompromised | Anti-pseudomonal beta-lactam (e.g., meropenem, cefepime) ± vancomycin or linezolid (MRSA coverage) |
| Suspected fungal (prolonged ICU stay, TPN, immunosuppression) | Add echinocandin (e.g., micafungin, caspofungin) |
| Intra-abdominal source | Piperacillin-tazobactam OR meropenem + metronidazole |
| Meningitis | Ceftriaxone + vancomycin + ampicillin (if Listeria risk) + dexamethasone |
De-escalation
- Review cultures and sensitivities at 48–72 hours
- Narrow spectrum as soon as the pathogen is identified
- Target 7–10 days for most infections; shorter courses when clinically appropriate
- Use procalcitonin to guide cessation of therapy
6. Vasopressors & Hemodynamic Support
| Agent | Role | Notes |
|---|---|---|
| Norepinephrine | First-line vasopressor | Preferred; start at 0.1–0.2 mcg/kg/min, titrate to MAP ≥65 mmHg |
| Vasopressin | Second-line add-on | 0.03–0.04 units/min; used to reduce norepinephrine dose (not to increase MAP further) |
| Epinephrine | Third-line / refractory shock | Add when norepinephrine + vasopressin insufficient |
| Dopamine | Avoid in most patients | Reserve for patients at highest risk of tachyarrhythmias or with relative bradycardia |
| Dobutamine | Cardiogenic component | Add if low cardiac output persists despite adequate preload and MAP |
Target MAP ≥65 mmHg — higher targets (e.g., 80–85 mmHg) do not improve outcomes in most patients and may increase arrhythmia risk.
7. Source Control
- Identify the focus of infection within 6–12 hours
- Drain abscesses, debride infected tissue, remove infected devices (lines, catheters, prostheses)
- Operative vs. percutaneous drainage: choose the least invasive effective option
- Remove intravascular access devices that are the suspected source immediately
8. Organ Support
Respiratory
- Intubate for refractory hypoxemia, respiratory failure, or reduced consciousness (GCS ≤8)
- Lung-protective ventilation: tidal volume 6 mL/kg IBW, plateau pressure <30 cmH₂O
- Target SpO₂ 92–96%; avoid hyperoxia
- Prone positioning ≥16 hours/day for moderate-severe ARDS (PaO₂/FiO₂ <150)
- Consider high-flow nasal oxygen (HFNO) or NIV as a bridge before intubation
Renal
- Avoid nephrotoxins where possible
- Initiate continuous renal replacement therapy (CRRT) for:
- Refractory fluid overload
- Severe acidosis (pH <7.15)
- Hyperkalemia unresponsive to medical management
- Uremia with encephalopathy or pericarditis
Cardiovascular
- Maintain euvolemia; avoid fluid overload (target net zero to negative fluid balance after initial resuscitation)
- Monitor with arterial line (continuous MAP) + central venous access
9. Corticosteroids
| Indication | Regimen |
|---|---|
| Refractory septic shock (vasopressors not controlling MAP despite adequate fluids) | Hydrocortisone 200 mg/day IV (50 mg q6h or continuous infusion) |
| Duration | Until vasopressors are weaned; typically 5–7 days |
| Avoid routine use in sepsis without shock | — |
Fludrocortisone 50 mcg/day oral may be added alongside hydrocortisone per individual unit protocols.
10. Glycemic Control
- Target blood glucose 140–180 mg/dL (7.8–10 mmol/L)
- Use insulin infusion protocol for ICU patients
- Check glucose every 1–2 hours until stable, then every 4 hours
- Avoid hypoglycemia — associated with increased mortality
11. Additional Supportive Measures
| Intervention | Recommendation |
|---|---|
| DVT prophylaxis | LMWH (preferred) or UFH; mechanical if anticoagulation contraindicated |
| Stress ulcer prophylaxis | PPI or H₂ blocker for patients on mechanical ventilation or with coagulopathy |
| Nutrition | Initiate enteral nutrition within 24–48 hours of ICU admission; avoid parenteral nutrition in early phase if GI tract functional |
| Sedation | Minimize; use light sedation protocols (RASS target -1 to 0); prefer short-acting agents (propofol, dexmedetomidine) |
| Analgesia | Analgesia-first approach (analgosedation); fentanyl or morphine |
| Early mobility | Physiotherapy and passive/active mobilization as soon as hemodynamically stable |
| Head-of-bed elevation | 30–45° to reduce VAP risk |
12. Monitoring Targets
| Parameter | Target |
|---|---|
| MAP | ≥65 mmHg |
| Lactate | <2 mmol/L; clearance ≥10% per 2 hours |
| SpO₂ | 92–96% |
| Urine output | ≥0.5 mL/kg/hour |
| Blood glucose | 140–180 mg/dL |
| Temperature | Treat fever (>38.5°C) or hypothermia (<36°C) |
| CVP / ScvO₂ | Use as trend markers, not absolute targets |
13. De-escalation & ICU Discharge Criteria
- Vasopressors weaned off
- Lactate normalized
- Off mechanical ventilation or stable on low-support NIV
- Antibiotics narrowed/oral switch feasible
- Adequate analgesia without IV infusions
- Able to tolerate enteral nutrition
- Consistent urine output without RRT
14. Post-Sepsis Considerations
- Post-intensive care syndrome (PICS): screen for cognitive impairment, PTSD, physical deconditioning at ICU follow-up
- Functional rehabilitation: early physiotherapy and occupational therapy referral
- Antibiotic stewardship review: audit culture results and antibiotic duration
- Family communication: structured updates throughout ICU stay
References: Harrison's Principles of Internal Medicine, 21st Ed. (p. 8273); Bailey & Love's Short Practice of Surgery, 28th Ed. (p. 80); Surviving Sepsis Campaign Guidelines 2021 (Rhodes et al., Intensive Care Med / Crit Care Med)
This is a shared conversation. Sign in to Orris to start your own chat.